ArticleAesthetic plastic surgery2026
Piezo1-A Key Pathogenic Factor in Breast Implant-Associated Capsular Contracture.
Article in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of Pentoxifylline on Peri-Implant Capsule Cellularity and Thickness: A Controlled Experimental Study in a Rat Silicone Implant Model.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCapsular contracture (CC) remains one of the most common complications following breast implant surgery, yet its underlying mechanisms are not fully clarified. The mechanosensitive ion channel Piezo1 has been implicated in fibrotic processes across various organs; however, its role in breast implant-associated fibrosis remains unknown.
objectiveThis study aimed to investigate the expression and functional significance of Piezo1 in the pathogenesis of breast implant-associated capsular contracture.
methodsUsing a murine silicone-implanted model, we analyzed expression of Piezo1 during capsule formation. Human capsular tissues (normal and contracted) were examined for Piezo1 expression. A lipoteichoic acid (LTA)-induced contracture model was employed to assess the therapeutic effect of GsMTx4, a specific Piezo1 inhibitor. Evaluations included histology, immunofluorescence, and Western blot analysis.
resultsPiezo1 expression was significantly upregulated during early capsule formation in mice, showing a correlating with collagen deposition and capsular thickening. Patients contracted capsules exhibited markedly higher Piezo1 levels compared to normal capsules. In the LTA-induced contracture model, pharmacological inhibition of Piezo1 with GsMTx4 substantially reduced collagen deposition, capsular thickness, and Piezo1 expression levels.
conclusionOur findings establish Piezo1 as a critical mediator in the pathogenesis of breast implant-associated capsular contracture. The channel's dynamic expression and the efficacy of its inhibition highlight its pivotal role in the fibrotic process. Piezo1 represents a novel target, offering a promising therapeutic strategy for preventing this challenging complication. LEVEL OF EVIDENCE V: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
41559393What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.